Trusted Resources: Education
Scientific literature and patient education texts
Drug Delivery for Neuronopathic Lysosomal Storage Diseases: Evolving Roles of the Blood Brain Barrier and Cerebrospinal Fluid
source: Metabolic brain disease
year: 2022
authors: Sato Y,Minami K,Hirato T,Tanizawa K,Sonoda H,Schmidt M
summary/abstract:Whereas significant strides have been made in the treatment of lysosomal storage diseases (LSDs), the neuronopathy associated with these diseases remains impervious mainly because of the blood-brain barrier (BBB), which prevents delivery of large molecules to the brain. However, 100 years of research on the BBB since its conceptualization have clarified many of its functional and structural characteristics, spurring recent endeavors to deliver therapeutics across it to treat central nervous system (CNS) disorders, including neuronopathic LSDs. Along with the BBB, the cerebrospinal fluid (CSF) also functions to protect the microenvironment of the CNS, and it is therefore deeply involved in CNS disorders at large. Recent research aimed at developing therapeutics for neuronopathic LSDs has uncovered a number of critical roles played by the CSF that require further clarification. This review summarizes the most up-to-date understanding of the BBB and the CSF acquired during the development of therapeutics for neuronopathic LSDs, and highlights some of the associated challenges that require further research.
organization: Research and Development, JCR Pharmaceuticals, Ashiya, Hyogo, Japan. [email protected].DOI: 10.1007/s11011-021-00893-3
read more
Related Content
-
The First Mucopolysaccharidosis Type VII in a Taiwanese Girl: A Case Report and Review of the LiteratureThe present study included the first cas...
-
A Guide to Understanding MPS I (Hurler, Hurler-Scheie, and Scheie Syndromes)What Is MPS I? Mucopolysaccharidosis I (...
-
UPMC Children’s Hospital of Pittsburgh – Center for Rare Disease TherapyHurler syndrome (mucopolysaccharidosis t...
-
Mucopolysaccharidosis Conditions Explainedhttps://www.youtube.com/watch?v=EmSJ_hGE...
-
Therapy-Type Related Long-Term Outcomes in Mucopolysaccaridosis Type II (Hunter Syndrome) – Case SeriesMucopolysaccharidosis type II (MPS II, H...
-
Genome Editing in Mucopolysaccharidoses and MucolipidosesMucopolysaccharidoses (MPS) and mucolipi...
-
Mucopolysaccharidoses Diagnosis in the Era of Enzyme Replacement Therapy in EgyptUndegraded glycosaminoglycans (GAGs) ind...